ONO-4538 + Placebo

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastric Cancer

Conditions

Gastric Cancer

Trial Timeline

Oct 1, 2014 → Jan 1, 2021

About ONO-4538 + Placebo

ONO-4538 + Placebo is a phase 3 stage product being developed by Ono Pharmaceutical for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02267343. Target conditions include Gastric Cancer.

What happened to similar drugs?

5 of 20 similar drugs in Gastric Cancer were approved

Approved (5) Terminated (3) Active (13)
ApatinibTabletsJiangsu Hengrui MedicineApproved
ApatinibJiangsu Hengrui MedicineApproved
Esomeprazole SodiumAstraZenecaApproved
trastuzumab [Herceptin]RocheApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02267343Phase 3Completed